Hoth Therapeutics Inc. Announces the Addition of Dr. Adam Friedman, M.D. to the Company's Scientific Advisory Board

Hoth Therapeutics, Inc.(NASDAQ: HOTH ), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema, today announced the addition of Dr. Adam Friedman, M.D., to the Company's Scientific Advisory Board. The Scientific Advisory Board was formed to assist the Company in developing the BioLexa Platform. The BioLexa Platform is a proprietary, patented, drug compound platform developed at the University of Cincinnati.

Adam Friedman, MD, FAAD is Professor and Interim Chair of Dermatology and serves as Residency Program Director and Director of Translational Research in the Department of Dermatology at The George Washington University School of Medicine & Health Sciences. Dr. Friedman completed his undergraduate training at the University of Pennsylvania and graduated with Distinction in Dermatologic Research at the Albert Einstein College of Medicine in New York. He completed his internship at New York Hospital Queens and returned to Einstein for his Dermatology residency, where he was appointed Chief Resident during his final year. Dr. Friedman joined the Einstein faculty after graduation and served as the Director of Dermatologic Research, Director of the Translational Research Fellowship, and the Associate Program Director.

Dr. Friedman’s clinical interests run the gamut of medical and pediatric dermatology including acne, eczema, psoriasis, skin infections, hair loss, wound healing, urticaria, blistering diseases, lupus, sarcoidosis, cannabinoids for the treatment of inflammatory, neoplastic diseases of the skin and skin cancer. He has published more than 170 papers and two textbooks on these topics and on his research using nanotechnologies he developed to treat many of these conditions. Dr. Friedman has received multiple awards, including the American Dermatologic Association Young Leader Award, the 2017 Elle Beauty Genius Award, the American Society for Dermatologic Surgery Cutting Edge Research Award, the Journal of Drugs in Dermatology Leader in Photoprotection Award, and the La Roche Posay North American Foundation Research Award. He has been voted as a Washingtonian Top Doctor since 2017.

About Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc., a Nevada corporation, is a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. Hoth has exclusive worldwide rights to the BioLexa Platform.

Forward Looking Statements Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the “SEC”), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact

Investor Relations Contact: Phone: (646) 756-2997 Email: investorrelations@hoththerapeutics.com www.hoththerapeutics.com